<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882827</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-014-MDYF</org_study_id>
    <nct_id>NCT03882827</nct_id>
  </id_info>
  <brief_title>Natural History of Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Prospective, Interventional, Baseline Study In Young Male Subjects Aged From 4 to 6 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Baseline Study on Duchenne Muscular Dystrophy (DMD) in view to collect data on the natural
      disease course in a cohort in young male subjects aged from 4 to 6 Years over a period of 6
      to 24 months using disease appropriate evaluations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration from FPFV: Q1 2019 to LPLV: Q3 2021

      Primary Ojectives:

        -  To assess the natural disease course using standardized and disease appropriate
           evaluations over a period of 6 to 24 months in a cohort of young male subjects aged from
           4 to 6 years at inclusion and diagnosed for Duchenne Muscular Dystrophy (DMD).

        -  To record a baseline period prior to the setup of an AAV gene therapy dose escalation
           phase I/II First in Man clinical study.

      Secondary Objectives:

        -  To identify clinical, imaging and/or laboratory parameters that could be predictive
           indicators of the disease course in DMD, within the selected range of age.

        -  To identify the best outcome measure(s) for further clinical trial assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NSAA scale</measure>
    <time_frame>Screening 24 months</time_frame>
    <description>NSAA scale (age appropriate modified North Star Ambulatory Assessment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10 Meter Walk/ Run test (10MW/RT)</measure>
    <time_frame>Screening 24 months</time_frame>
    <description>Time function Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Minutes Walk Test (6 MWT)</measure>
    <time_frame>Screening 24 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myoset : Myo-grip, -pinch</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTIMYO</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Imaging Nuclear Magnetic Resonance Imaging (NMRI)</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Muscle Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Test (PFT)</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Respiratory Function Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG - Echocardiography</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Cardiac Function Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTIVLIM</measure>
    <time_frame>Inclusion 24 months</time_frame>
    <description>Patient Reported Outcome</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male 4 to 6 years old inclusive Body-Weight the 70th percentile of WHO body-weight scale
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male

          2. 4 to 6 years old inclusive

          3. Body-Weight the 70th percentile of WHO body-weight scale

          4. Diagnosis of DMD based upon Gene testing positive with detailed genotyping

          5. Able to achieve:

               -  NSAA (North Star Ambulatory Assessment) scale 18 (with a maximum of 2 points
                  difference between inclusion and screening visits) and/or:

               -  Gowers test 7 sec

               -  6 Minute Walk Test (6MWT) 350 meters at screening visit (M1) and at inclusion
                  visit (M0) with the distance being 20% of each other

          6. Ongoing corticosteroid therapy or initiation of corticosteroid therapy according to
             standard of care in the previous 3 months

          7. Signed informed consent by at least one parent(s) in UK and both parents in France or
             legal guardian representative(s), when applicable

          8. Affiliated Beneficiary of the National Health Care scheme

             Exclusion Criteria:

          9. Cardiomyopathy based on physical cardiological examination and echocardiography with
             Left Ventricular Ejection Fraction (LVEF) below 55%

         10. Respiratory Assistance: need for either a diurnal and/or a nocturnal ventilation

         11. Any co-morbidity (ies) and or previous or planned surgical event(s) which may
             interfere with DMD natural evolution and or evaluation of outcomes designed to assess
             DMD Natural History

         12. Muscle testing: inability to cooperate with

         13. Nuclear Magnetic Resonance Imaging (NMRI): metal implants in regions of interest for
             the study

         14. Unwilling and/or unable to comply with all the study protocol requirements and or
             procedures

         15. Previous inclusion to another clinical trial with an Investigational Medicinal Product
             (IMP), within the 3 months (or IMP washout period) prior to the screening visit of the
             study

         16. Concomitant participation to any other clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco MUNTONI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOSH LONDON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco MUNTONI, Pr</last_name>
    <phone>+44 02079052602</phone>
    <email>m.zancolli@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital &amp; University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Genetic Medicine</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

